cagrilintide with semaglutide Co-formulation of and Shows Promise Against Diabetes and Obesity Cagrilintide and Semaglutide: CagriSema Weight

However, the loss of glycaemic control can lead to symptoms of hyperglycaemia (high blood sugar), including increased thirst, frequent urination, fatigue, and blurred vision

Phase 2 body composition substudy data using DEXA scans showed that retatrutide participants lost predominantly fat mass, with a favorable fat-to-lean mass loss ratio

Additional microbiological testing confirmed no detectable aerobic microorganisms, yeasts or moulds, supporting laboratory-grade quality standards suitable for controlled scientific investigation

Statistical analysis Baseline characteristics of participants were summarized as mean standard deviation (SD) for continuous variables and percentages for categorical variables